Assessment of the risk of malignancy in Bethesda III thyroid nodules: a comprehensive review

• The increasing prevalence of thyroid cancer emphasizes the need for a thorough assessment of risk of malignancy in Bethesda III nodules. Various methods ranging commercial platforms of molecular genetic testing (including Afirma (R) GEC, Afirma (R) GSC, ThyroSeq (R) V3, RosettaGX (R), ThyGeNEXT (R)/ThyraMIR (R), ThyroidPRINT (R)) to radionuclide scans and ultrasonography have been investigated to provide a more nuanced comprehension of risk estimation. The integration of molecular studies and imaging techniques into clinical practice may provide clinicians with improved and personalized risk assessment. This integrated approach we feel may enable clinicians to carefully tailor interventions, thereby minimizing the likelihood of unnecessary thyroid surgeries and overall crafting the optimal treatment. By aligning with the evolving landscape of personalized healthcare, this comprehensive strategy ensures a patient-centric approach to thyroid nodule and thyroid cancer management.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Thyroid neoplasms

Risk assessment

Molecular testing

Bethesda system

Artificial intelligence

Publikations- och innehållstyp

ref (ämneskategori)

for (ämneskategori)